429 related articles for article (PubMed ID: 26014133)
1. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
4. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
Zhu Q; Sun Y; Cui Y; Ye K; Yang C; Yang D; Ma J; Liu X; Yu J; Ge H
Oncotarget; 2017 Feb; 8(8):13304-13311. PubMed ID: 28076323
[TBL] [Abstract][Full Text] [Related]
6. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
7. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.
Hirata H; Nakamura K; Kunitake N; Shioyama Y; Sasaki T; Ohga S; Nonoshita T; Yoshitake T; Asai K; Inoue K; Nagashima A; Ono M; Honda H
Anticancer Res; 2013 Apr; 33(4):1649-55. PubMed ID: 23564810
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
9. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated
Non-small Cell Lung Cancer and Brain Metastases].
Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
[TBL] [Abstract][Full Text] [Related]
12. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
13. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
[TBL] [Abstract][Full Text] [Related]
14. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
Soon YY; Leong CN; Koh WY; Tham IW
Radiother Oncol; 2015 Feb; 114(2):167-72. PubMed ID: 25583566
[TBL] [Abstract][Full Text] [Related]
15. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
16. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Chang YC; Lin MC
PLoS One; 2015; 10(8):e0136252. PubMed ID: 26313661
[TBL] [Abstract][Full Text] [Related]
17. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
20. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
